Abivertinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor that irreversibly targets BTK. BTK inhibitors are a large category in...
Conference Call Scheduled for July 6, 2023 at 11:00 am EASTERNDUBLIN, July 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:...
CARLSBAD, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management...
HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to...
Highly experienced international Board Leader joins Emergex as the company grows and progresses clinical development of its pipeline of T...
CALGARY, Alberta, June 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
The Phase 3 study of Ovydso was initiated in China in February 2023 and enrolled and dosed 1,200 COVID-19 patients...
In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients to complete protocol-defined islet transplants...
The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26,...
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively...
Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE)...
Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) --...
DELRAY BEACH, Fla., June 20, 2023 (GLOBE NEWSWIRE) -- UpHealth, Inc., a global digital health company delivering technology platforms, infrastructure,...
Emergex and Brazil’s IBMP to co-fund Phase II and Phase III studies of Emergex’s Dengue Fever and Betacoronavirus T cell-priming...
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12...
LPAD may provide alternative pathways for streamlined product approvalLOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc....
Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatmentsLEHI,...
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded...
New panel will enable rapid, precise genetic profiling of patients with deadly diseaseNEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE)...
Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust...